Shares of Tenax Therapeutics jumped 9.4% to $2.33 after the company presented detailed data from its pivotal heart-drug trial at Europe's largest cardiology conference — results that offered investors a lifeline after a brutal ~85% sell-off earlier this month when the trial's main goal fell short.
The Drug Failed Its Overall Test, but a Subset of Sicker Patients Responded
In the full 241-patient study, the drug did not produce a statistically significant improvement in how far patients could walk in six minutes — the trial's primary measure. But in patients who started with worse walking ability (below 333 meters), the drug added 26.3 meters versus placebo (p = 0.0112), cut a key cardiac stress marker called NT-proBNP by 47%, and lowered lung-artery pressure by 4.9 mmHg . That's a coherent biological signal, but regulators typically want a win in the whole study population, not just a slice of it.
The Company Is Pivoting Its Strategy Around These Findings
Tenax plans to request an FDA meeting to present the full dataset and seek guidance from European regulators in parallel . Critically, the FDA had previously agreed that a single successful Phase 3 trial — with a stricter statistical bar of p = 0.01 — could support a drug application . Tenax now wants to "enrich" its next study, LEVEL-2, by focusing on sicker patients most likely to benefit. That global trial is ongoing, with enrollment expected to finish by end of 2027 . If the FDA accepts this narrower patient pool, LEVEL-2 becomes the make-or-break moment.
Cash Buys Time, but the Burn Rate Is Steep
Tenax posted a $17.8 million net loss in Q2 2026, with R&D spending of $12.9 million and roughly $118 million in cash . Management says that's enough to fund operations through the second quarter of 2028 . That runway covers the LEVEL-2 enrollment window but likely not the full readout. More fundraising — meaning potential dilution for existing shareholders — looks probable.
A Huge Unmet Need, but No Guaranteed Path to Fill It
Tenax holds global rights to develop its drug for PH-HFpEF, the most common form of pulmonary hypertension, for which no therapy has been approved . U.S. prevalence alone is estimated at over two million patients . The market opportunity is real, but it now hinges entirely on whether a redesigned study in a narrower group can deliver the clean win the first trial didn't. At $2.33, investors are pricing in long odds — and the next catalyst is years away.